KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Teva Pharmaceutical Industries (TEVA) Net Margin (2016 - 2025)

Historic Net Margin for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to 14.56%.

  • Teva Pharmaceutical Industries' Net Margin rose 212300.0% to 14.56% in Q4 2025 from the same period last year, while for Dec 2025 it was 9.28%, marking a year-over-year increase of 202800.0%. This contributed to the annual value of 8.11% for FY2025, which is 200000.0% up from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Net Margin stood at 14.56% for Q4 2025, which was up 212300.0% from 9.55% recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Net Margin's 5-year high stood at 14.56% during Q4 2025, with a 5-year trough of 54.79% in Q4 2022.
  • Moreover, its 5-year median value for Net Margin was 19.49% (2021), whereas its average is 19.1%.
  • Within the past 5 years, the most significant YoY rise in Teva Pharmaceutical Industries' Net Margin was 918800bps (2021), while the steepest drop was -306100bps (2021).
  • Teva Pharmaceutical Industries' Net Margin (Quarter) stood at 27.24% in 2021, then plummeted by -101bps to 54.79% in 2022, then increased by 1bps to 54.21% in 2023, then soared by 88bps to 6.67% in 2024, then soared by 318bps to 14.56% in 2025.
  • Its Net Margin was 14.56% in Q4 2025, compared to 9.55% in Q3 2025 and 6.56% in Q2 2025.